BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Stock analysts at SunTrust Banks increased their FY2017 earnings estimates for BioMarin Pharmaceutical in a research note issued to investors on Monday. SunTrust Banks analyst E. Nash now forecasts that the biotechnology company will post earnings of ($0.56) per share for the year, up from their prior forecast of ($0.58). SunTrust Banks currently has a “Buy” rating and a $115.00 target price on the stock. SunTrust Banks also issued estimates for BioMarin Pharmaceutical’s Q4 2017 earnings at ($0.18) EPS, Q1 2018 earnings at ($0.11) EPS, Q2 2018 earnings at ($0.07) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at ($0.05) EPS, FY2018 earnings at ($0.34) EPS, FY2019 earnings at $0.49 EPS and FY2020 earnings at $0.10 EPS.

BMRN has been the subject of a number of other research reports. Morgan Stanley reissued an “overweight” rating and issued a $117.00 target price (up previously from $115.00) on shares of BioMarin Pharmaceutical in a report on Friday, October 6th. Stifel Nicolaus dropped their target price on shares of BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating for the company in a report on Friday, October 27th. BMO Capital Markets reissued a “buy” rating and issued a $117.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, October 20th. Goldman Sachs Group reissued a “buy” rating and issued a $129.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, October 6th. Finally, J P Morgan Chase & Co set a $130.00 target price on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Sunday, October 29th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the company’s stock. BioMarin Pharmaceutical has a consensus rating of “Hold” and an average target price of $111.59.

BioMarin Pharmaceutical (NASDAQ:BMRN) opened at $85.00 on Thursday. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical has a fifty-two week low of $79.50 and a fifty-two week high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The firm had revenue of $334.18 million during the quarter, compared to analysts’ expectations of $347.38 million. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The business’s revenue for the quarter was up 19.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.02 earnings per share.

In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 15,000 shares of the stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $90.50, for a total transaction of $1,357,500.00. Following the completion of the sale, the insider now owns 141,422 shares of the company’s stock, valued at approximately $12,798,691. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey Robert Ajer sold 3,521 shares of the stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $95.00, for a total transaction of $334,495.00. Following the sale, the executive vice president now directly owns 49,299 shares of the company’s stock, valued at approximately $4,683,405. The disclosure for this sale can be found here. Insiders sold 40,686 shares of company stock valued at $3,736,318 in the last ninety days. 1.85% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in BMRN. Jennison Associates LLC increased its position in BioMarin Pharmaceutical by 33.8% during the 2nd quarter. Jennison Associates LLC now owns 13,242,773 shares of the biotechnology company’s stock valued at $1,202,709,000 after purchasing an additional 3,348,168 shares during the period. TIAA CREF Investment Management LLC grew its position in shares of BioMarin Pharmaceutical by 63.7% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 2,251,011 shares of the biotechnology company’s stock worth $204,437,000 after buying an additional 875,686 shares during the period. USS Investment Management Ltd grew its position in shares of BioMarin Pharmaceutical by 214.7% during the 2nd quarter. USS Investment Management Ltd now owns 1,089,933 shares of the biotechnology company’s stock worth $98,988,000 after buying an additional 743,599 shares during the period. Vanguard Group Inc. grew its position in shares of BioMarin Pharmaceutical by 4.7% during the 2nd quarter. Vanguard Group Inc. now owns 14,345,027 shares of the biotechnology company’s stock worth $1,302,816,000 after buying an additional 642,623 shares during the period. Finally, Teachers Advisors LLC grew its position in shares of BioMarin Pharmaceutical by 41.7% during the 2nd quarter. Teachers Advisors LLC now owns 973,291 shares of the biotechnology company’s stock worth $88,394,000 after buying an additional 286,249 shares during the period. 99.31% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/biomarin-pharmaceutical-inc-bmrn-to-post-fy2017-earnings-of-0-56-per-share-suntrust-banks-forecasts/1738680.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.